NCT04161001 - Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451 | Biotech Hunter

Enrollment

237

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

November 20, 2021

Study Completion Date

February 2, 2022

Conditions

Hypertension, Dyslipidemia

Interventions

DRUG

Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)

co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)

DRUG

Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)

co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)

DRUG

Amlodipine/Olmesartan 10/40mg (Combination drug)

co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)

Trial Locations (1)

Unknown

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul